Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 90
Filter
1.
Osteoporos Int ; 21(5): 805-14, 2010 May.
Article in English | MEDLINE | ID: mdl-19876583

ABSTRACT

UNLABELLED: The phenotypic and functional characteristics of immune cells of osteoporotic women compared to healthy controls similar for age and estrogen level showed for the first time significant changes in several B lymphocytes populations in postmenopausal osteoporosis, related to bone mineral density (BMD) and fractures, and a significant lower basal secretion of interferon-gamma (IFN-gamma) by CD4(+). INTRODUCTION: To investigate the interactions between bone and immune system, we studied the phenotypic and functional characteristics of immune cells of 26 postmenopausal women with osteoporotic (OP) fractures compared to 24 healthy controls. METHODS: We analyzed surface markers of peripheral B, CD4(+) and CD8(+) lymphocytes and cytokine secretion in supernatants of these cells cultured with or without stimulation. Body composition was assessed by dual energy X-ray absorptiometry. RESULTS: The two groups were similar for age and estrogen level. OP women had a significantly lower body mass index, fat mass, and lean mass. The number of CD19(+), CD19(+)/CD27(+), CD19(+)/CD27(+)/CD5(-)/CD38(+) and CD19(+)/CD27(+)/RANK(+), CD4(+)/CD27(+)/CD45RA(-)/RANK(+), and CD4(+)/CD27(+)/CD45RA(-)/CD28(+) was lower in OP women and positively correlated to BMD. In OP women, under basal conditions, CD4(+) secreted less IFN-gamma and B lymphocytes more granulocyte macrophage colony-stimulating factor (GM-CSF). GM-CSF was positively correlated to fracture rate and negatively to BMD. CONCLUSIONS: Our results suggest that, regardless of age and estrogen status, postmenopausal OP is associated with immune changes, highlighting a possible role of IFN-gamma in the pathophysiology of OP and reporting, for the first time, changes in several B lymphocyte populations. These alterations may reflect the frailty observed after fracture, providing new insight into the mechanisms of morbidity and mortality associated with OP fractures.


Subject(s)
Osteoporosis, Postmenopausal/immunology , Aged , Aged, 80 and over , B-Lymphocyte Subsets/immunology , Body Composition/physiology , Case-Control Studies , Dendritic Cells/immunology , Estrogens/blood , Female , Granulocyte-Macrophage Colony-Stimulating Factor/biosynthesis , Humans , Immunity, Cellular , Immunophenotyping , Interferon-gamma/biosynthesis , Middle Aged , Osteoporosis, Postmenopausal/blood , Osteoporosis, Postmenopausal/physiopathology , Osteoporotic Fractures/immunology , Osteoporotic Fractures/physiopathology , Pilot Projects , T-Lymphocyte Subsets/immunology
2.
Eur J Clin Microbiol Infect Dis ; 28(6): 575-84, 2009 Jun.
Article in English | MEDLINE | ID: mdl-19229566

ABSTRACT

T-cell apoptosis during septic shock (SS) has been associated with deleterious outcome, but the mechanisms of apoptosis are not well understood. As T-cells are not infected in bacterial infection, our hypothesis was that deleterious interactions between lymphocytes and monocytes could be involved. This is a cross-sectional study of 27 patients presenting with community-acquired SS, 23 infected patients without SS and 18 controls. Cytofluorometric techniques were used to study apoptosis, the costimulatory pathway and cytokine synthesis. Apoptosis was increased in SS compared to infected patients without SS and controls: the median values were 18, 2 and 3%, respectively, for CD4(+) T-cells (P < 0.001), and 12, 5 and 2%, respectively, for CD8(+) T-cells (P < 0.001). Patients with SS exhibited significant CD152 over-expression on T-cells, while CD86 expression was decreased on monocytes (P = 0.004). The synthesis of interleukin-2 was decreased in patients with SS compared to the other groups, while secretions of interferon-gamma and TNF-alpha were not altered. Ten surviving patients with SS showed a trend towards the normalisation of these parameters on day 7. In SS, T-cell apoptosis is related, at least in part, to the alteration of the costimulatory pathway, which, in turn, leads to significant modification of the cytokine network.


Subject(s)
Apoptosis , Shock, Septic/immunology , T-Lymphocytes/immunology , Adult , Aged , Aged, 80 and over , Antigens, CD/biosynthesis , B7-2 Antigen/biosynthesis , CTLA-4 Antigen , Female , Flow Cytometry , Humans , Interferon-gamma/metabolism , Interleukin-2/metabolism , Male , Middle Aged , Monocytes/immunology , Tumor Necrosis Factor-alpha/metabolism
3.
Oncogene ; 26(17): 2445-58, 2007 Apr 12.
Article in English | MEDLINE | ID: mdl-17043649

ABSTRACT

Imatinib targets the Bcr-Abl oncogene that causes chronic myelogenous leukemia (CML) in humans. Recently, we demonstrated that besides triggering apoptosis in K562 cells, imatinib also mediated their erythroid differentiation. Although both events appear to proceed concomitantly, it is not known at present whether or not imatinib-induced apoptosis and differentiation are interdependent processes. Hence, we investigated the requirements for Bcr-Abl inhibitor-mediated apoptosis and erythroid differentiation in several established and engineered CML cell lines. Imatinib triggered apoptosis and erythroid differentiation of different CML cell lines, but only apoptosis exhibited sensitivity to ZVAD-fmk inhibition. Conversely, the p38 mitogen-activated protein (MAP) kinase inhibitor, SB202190, significantly slowed down erythroid differentiation without affecting caspase activation. Furthermore, imatinib and PD166326, another Bcr-Abl inhibitory molecule, triggered erythroid differentiation of K562 cell clones, nevertheless resistant to Bcr-Abl inhibitor-induced apoptosis. Finally, short hairpin RNA inhibitor (shRNAi) silencing of caspase 3 efficiently inhibited caspase activity but had no effect on erythroid differentiation, whereas silencing of Bcr-Abl mimicked imatinib or PD166326 treatment, leading to increased apoptosis and erythroid differentiation of K562 cells. Taken together, our findings not only demonstrate that Bcr-Abl inhibitor-mediated apoptosis and differentiation are fully distinguishable events, but also that caspases are dispensable for erythroid differentiation of established CML cell lines.


Subject(s)
Apoptosis/drug effects , Caspase Inhibitors , Cell Differentiation/drug effects , Enzyme Inhibitors/pharmacology , Leukemia, Myelogenous, Chronic, BCR-ABL Positive/enzymology , Protein-Tyrosine Kinases/antagonists & inhibitors , Benzamides , Caspases/metabolism , Cell Line, Tumor , Enzyme Activation/drug effects , Erythroid Cells/cytology , Erythroid Cells/enzymology , Erythroid Cells/pathology , Fusion Proteins, bcr-abl , Humans , Imatinib Mesylate , K562 Cells , Leukemia, Myelogenous, Chronic, BCR-ABL Positive/blood , Leukemia, Myelogenous, Chronic, BCR-ABL Positive/drug therapy , Piperazines/pharmacology , Protein-Tyrosine Kinases/blood , Pyridines/pharmacology , Pyrimidines/pharmacology
4.
Scand J Immunol ; 62(2): 168-75, 2005 Aug.
Article in English | MEDLINE | ID: mdl-16101824

ABSTRACT

Hepatitis C virus (HCV) infection leads to liver injury, which is thought to be immune-mediated. Apoptosis of hepatic T cells could influence histological damage. We quantified peripheral and intrahepatic T-cell apoptosis in 28 patients with chronic hepatitis C by using cytofluorometric techniques. METAVIR score and HCV plasma viral load were determined. Six liver biopsies, obtained from controls without chronic hepatitis during hepatobiliary surgery, served as controls. In patients, liver T-cell apoptosis was upregulated compared to peripheral T cells: 35 versus 7% for CD4+ and 56 versus 13% for CD8+ T cells (P < 0.001). Liver T-cell apoptosis levels from patients were increased compared to controls for both CD4+ (P = 0.041) and CD8+ T cells (P = 0.007). Nine patients exhibiting METAVIR scores A and F < or = 1 showed higher intrahepatic CD4+ T-cell apoptosis compared to the 19 patients with a higher METAVIR score (P = 0.001) and both histological activity and fibrosis were related to apoptosis level. There was also an inverse relationship between the level of intrahepatic CD8+ T-cell apoptosis and serum transaminase activity (P = 0.023). Our study shows immune compartmentalization, suggesting that the study of peripheral blood lymphocytes may not be fully relevant to the pathophysiology of HCV hepatitis, and that the severity of liver injury is inversely correlated with intrahepatic CD4+ T-cell apoptosis.


Subject(s)
Apoptosis/immunology , CD4-Positive T-Lymphocytes/immunology , Hepacivirus/immunology , Hepatitis C/immunology , Liver/immunology , Adult , Aged , Benzimidazoles/chemistry , Biopsy, Fine-Needle , CD4-Positive T-Lymphocytes/pathology , CD4-Positive T-Lymphocytes/virology , CD8-Positive T-Lymphocytes/immunology , CD8-Positive T-Lymphocytes/virology , Female , Flow Cytometry , Fluorescent Dyes/chemistry , Hepatitis C/pathology , Hepatitis C/virology , Hepatocytes/immunology , Hepatocytes/virology , Humans , Liver/pathology , Liver Cirrhosis/immunology , Liver Cirrhosis/virology , Male , Middle Aged , Transaminases/blood , Viral Load
5.
Biochim Biophys Acta ; 1539(3): 256-64, 2001 Jun 20.
Article in English | MEDLINE | ID: mdl-11420123

ABSTRACT

Incubation of Jurkat cells in the presence of H2O2 either directly added to the culture medium or generated with glucose oxidase, menadione or the couple xanthine/xanthine oxidase induced a marked decrease of phosphatidylserine synthesis in the absence of changes in the synthesis of phosphatidylcholine and phosphatidylethanolamine. Concentration dependent response curves indicated that H2O2 induced inhibition of phosphatidylserine synthesis with an IC(50)=5 microM while both induction of tyrosine phosphorylation of proteins and Ca(2+) signals were obtained with an EC(50)=300 microM. The tyrosine kinase and Ca(2+) independent mechanism was confirmed by comparing the H2O2-induced and the CD3-induced inhibition of phosphatidylserine synthesis using several Jurkat clones differing in the expression of cell surface receptors such as CD3/TCR and CD45 and protein tyrosine kinase such as p72syk, ZAP-70 and p56lck. While CD3-induced inhibition of phosphatidylserine synthesis necessitates protein tyrosine phosphorylation and Ca(2+) signals, H2O2 provoked its effect in all the clones studied independently of the presence or absence of the proteins previously shown to be key elements in T cell signal transduction. Conversely, the antioxidant molecule, butylated hydroxanisole, generates an increased PtdSer synthesis, suggesting that the synthesis of this phospholipid is regulated by the redox status of the cells.


Subject(s)
Hydrogen Peroxide/pharmacology , Phosphatidylserines/biosynthesis , T-Lymphocytes/drug effects , Antioxidants/pharmacology , Biological Transport , Butylated Hydroxyanisole/pharmacology , Calcium/metabolism , Cell Survival/drug effects , Drug Interactions , Humans , Jurkat Cells , Protein-Tyrosine Kinases/metabolism , Reactive Oxygen Species/metabolism , T-Lymphocytes/metabolism
6.
J Antimicrob Chemother ; 47(1): 109-12, 2001 Jan.
Article in English | MEDLINE | ID: mdl-11152441

ABSTRACT

Apoptosis is one of the mechanisms involved in the persistent CD4(+) T cell lymphopenia occurring in human immunodeficiency virus (HIV)-infected patients treated with highly active antiretroviral therapy (HAART). The aim of this study was to look at the relationship between the level of T cell apoptosis in patients on HAART and their HIV viral load measurement. Forty-five patients receiving HAART for a median time of 5 months were included: 13 had an undetectable viral load and 32 had a viral load > or = 200 copies/mL. No relationship was observed between the level of spontaneous T cell apoptosis and the viral load measurement. Patients with a viral load > or = 200 copies/mL exhibited a significantly higher level of CD4-induced apoptosis of CD4(+) T cells, compared with patients with undetectable viraemia (38 versus 15%, respectively, P = 0.03). Activation-induced apoptosis may be involved in the paucity of the immune reconstitution observed in HIV-infected patients treated with HAART.


Subject(s)
Apoptosis , CD4-Positive T-Lymphocytes/pathology , HIV Infections/pathology , HIV/physiology , Viral Load , Adult , Antiretroviral Therapy, Highly Active/adverse effects , Female , HIV Infections/drug therapy , HIV Infections/immunology , HIV Infections/virology , Humans , Male , Middle Aged
7.
J Immunol ; 165(10): 5637-45, 2000 Nov 15.
Article in English | MEDLINE | ID: mdl-11067920

ABSTRACT

Infection of BALB/c mice with Leishmania major results in the rapid accumulation of IL-4 transcripts within CD4(+) T cells that react to the parasite Leishmania homologue of mammalian RACK1 (LACK) Ag. Because memory/effector cells secrete IL-4 more rapidly than naive cells, we sought to analyze the phenotype of these lymphocytes before infection. Indeed, a fraction of LACK-specific CD4(+) T cells expressed a typical CD62 ligand(low)CD44(high)CD45RB(low) phenotype in uninfected mice. LACK-specific T cells were primed in gut-associated lymphoid tissues by cross-reactive microbial Ags as demonstrated by their reactivity with bacterial extracts and by the ability of APCs from the mesenteric LN of BALB/c mice to induce their proliferation. Also, mice in which the digestive tract has been decontaminated exhibited a reduced proportion of LACK-specific T cells expressing a memory/effector phenotype and did not exhibit the early accumulation of IL-4 transcripts induced by L. major. Thus, LACK-specific T cells represent a subset of CD4(+) T cells which have acquired the ability to rapidly secrete IL-4 as the result of their priming by cross-reactive microbial Ags. Tracking the fate of these cells may provide information about the regulation of cell-mediated immune responses to gut Ags in physiological and pathological situations.


Subject(s)
Antigens, Bacterial/immunology , CD4-Positive T-Lymphocytes/immunology , Interleukin-4/metabolism , Intestinal Mucosa/immunology , Intestinal Mucosa/microbiology , Leishmania major/immunology , Leishmaniasis, Cutaneous/immunology , Lymphocyte Activation/immunology , ATP-Binding Cassette Transporters/genetics , ATP-Binding Cassette Transporters/immunology , Amino Acid Sequence , Animals , Anti-Bacterial Agents/pharmacology , Antibodies, Monoclonal/administration & dosage , Bacterial Proteins/genetics , Bacterial Proteins/immunology , CD4-Positive T-Lymphocytes/cytology , CD4-Positive T-Lymphocytes/metabolism , Cell Differentiation/immunology , Disease Susceptibility , Enterococcus faecalis/growth & development , Enterococcus faecalis/immunology , Epitopes, T-Lymphocyte/immunology , Escherichia coli/growth & development , Escherichia coli/immunology , Female , Germ-Free Life/immunology , Hybridomas , Injections, Intraperitoneal , Interleukin-4/biosynthesis , Interleukin-4/genetics , Interleukin-4/immunology , Intestinal Mucosa/drug effects , Leishmaniasis, Cutaneous/microbiology , Mice , Mice, Inbred BALB C , Mice, Nude , Mice, Transgenic , Molecular Sequence Data , RNA, Messenger/biosynthesis
8.
Mol Pharmacol ; 58(6): 1461-9, 2000 Dec.
Article in English | MEDLINE | ID: mdl-11093786

ABSTRACT

Derivatives of salicylic acid (SA) and benzoic acid prevent endothelin-1 (ET-1) binding to ETA receptors. This study analyzed actions of 30 derivatives of benzoic acid and salicylic acid on (125)I-ET-1 binding to recombinant rat ETA receptors. The most active compounds were 3,5-dibromosalicylic acid (Br2SA, K(i) = 0.5 mM) and 3,5-diiodosalicylic acid (K(i) = 0.3 mM). They were about 50 times more potent than SA and aspirin. Br2SA inhibited equilibrium (125)I-ET-1 binding in an apparently competitive manner. It accelerated 8-fold the dissociation of (125)I-ET-1 receptor complexes and did not modify the second order rate constant of association of (125)I-ET-1 to its receptors. Br2SA also decreased the affinity of ETA receptors for receptor antagonists BQ-123 and bosentan. Br2SA accelerated dissociation of (125)I-ET-1-solubilized ETA receptor complexes and decreased the apparent molecular size of solubilized receptors. Br2SA and 3,5-diiodosalicylic acid inhibited two cellular actions of ET-1: the mobilization of intracellular Ca(2+) stores in isolated cells and contractions of rat aortic rings. They accelerated the relaxing action of BQ-123 and bosentan in ET-1-treated aortic rings. The results suggest the existence of an allosteric modifier site on ETA receptors that recognizes selected derivatives of SA. SA derivatives might be of therapeutic interest to relieve tight ET-1 binding and to favor actions of receptor antagonists.


Subject(s)
Endothelin Receptor Antagonists , Endothelin-1/metabolism , Salicylates/pharmacology , Allosteric Regulation , Animals , Aorta/drug effects , Aorta/metabolism , Benzoic Acid/chemistry , Benzoic Acid/pharmacology , Biological Transport , Bosentan , Bromobenzoates , Calcium/metabolism , Cells, Cultured , Chromatography, Gel , Drug Interactions , Iodine Radioisotopes , Peptides, Cyclic/pharmacology , Rats , Receptor, Endothelin A , Receptors, Endothelin/metabolism , Recombinant Proteins/antagonists & inhibitors , Recombinant Proteins/metabolism , Salicylic Acid/chemistry , Salicylic Acid/pharmacology , Solubility , Sulfonamides/pharmacology , Vasodilation/drug effects
9.
Br J Pharmacol ; 129(7): 1506-12, 2000 Apr.
Article in English | MEDLINE | ID: mdl-10742308

ABSTRACT

1. Diadenosine polyphosphates (Ap(n)As, n=2 - 7) are considered as stress mediators in the cardiovascular system. They act both via identified P2 purinoceptors and via yet to be characterized receptors. This study analyses the actions of Ap(n)As in clones of rat brain capillary endothelial cells that express P2Y(1) receptors (B10 cells) or both P2Y(1) and P2Y(2) receptors (B7 cells). 2. B10 cells responded to Ap(3)A with rises in intracellular Ca(2+) concentration ([Ca(2+)](i)). This response was prevented by adenosine-3'-phosphate-5'-phosphate, an antagonist of P2Y(1) receptors. It was largely suppressed by a treatment with apyrase VII or with creatine phosphokinase/creatine phosphate to degrade contaminating ADP. 3. Ap(n)As inhibited ADP induced increases in [Ca(2+)](i) mediated by P2Y(1) receptors by shifting ADP concentration-response curves to larger concentrations. Apparent K(i) values were estimated to be 6 microM for Ap(4)A, 10 microM for Ap(5)A and 47 microM for Ap(6)A. Ap(2)A and Ap(3)A were much less active. 4. Ap(n)As were neither agonists nor antagonists of the endogenous P2Y(2) receptor in B7 cells. 5. Ap(n)As are neither agonists nor antagonists of the G(i)-coupled, ADP receptor in B10 cells. 6. The results suggest that most actions of Ap(n)As in B7 and B10 cells can be accounted for by endogenous P2Y(1) receptors. Ap(4)A, Ap(5)A and Ap(6)A are specific antagonists of endogenous Ca(2+)-coupled P2Y(1) receptors.


Subject(s)
Dinucleoside Phosphates/pharmacology , Endothelium, Vascular/drug effects , Purinergic P2 Receptor Antagonists , Adenosine Diphosphate/pharmacology , Adenylyl Cyclases/drug effects , Adenylyl Cyclases/metabolism , Animals , Brain/blood supply , Brain/cytology , Calcium/metabolism , Cells, Cultured , Clone Cells , Dose-Response Relationship, Drug , Endothelium, Vascular/cytology , Endothelium, Vascular/metabolism , Rats , Receptors, Purinergic P2/metabolism , Receptors, Purinergic P2Y1
10.
Mol Pharmacol ; 57(4): 797-804, 2000 Apr.
Article in English | MEDLINE | ID: mdl-10727528

ABSTRACT

Aspirin is a commonly used drug with a wide pharmacological spectrum including antiplatelet, anti-inflammatory, and neuroprotective actions. This study shows that aspirin and sodium salicylate, its major blood metabolite, reverse contractile actions of endothelin-1 (ET-1) in isolated rat aorta and human mammary arteries. They also prevent the intracellular Ca(2+) mobilizing action of ET-1 in cultured endothelial cells but not those of neuromedin B or UTP. Inhibition of the actions of ET-1 by salicylates is apparently competitive. Salicylates inhibit (125)I-ET-1 binding to recombinant rat ETA receptors. Salicylic acid promotes dissociation of (125)I-ET-1 ETA receptor complexes both in the absence and the presence of unlabeled ET-1. It has no influence on the rate of association of (125)I-ET-1 to ETA receptors. Salicylates do not promote dissociation of (125)I-ET-1 ETB receptor complexes. Salicylates potentiate relaxing actions of receptor antagonists such as bosentan. It is concluded that salicylates are allosteric inhibitors of ETA receptors. The results also suggest that: 1) irreversible ET-1 binding probably limits actions of receptor antagonists in vivo, and 2) an association of salicylates and ETA receptor antagonists should be used to evaluate the physiopathological role of ET-1 and may be of therapeutic interest in the treatment of ischemic heart disease.


Subject(s)
Anti-Inflammatory Agents, Non-Steroidal/pharmacology , Aspirin/pharmacology , Endothelin Receptor Antagonists , Sodium Salicylate/pharmacology , Allosteric Regulation/drug effects , Animals , Aorta , Biological Transport/drug effects , Bosentan , Calcium/metabolism , Cells, Cultured , Drug Synergism , Endothelin-1/metabolism , Humans , Mammary Arteries/drug effects , Muscle Contraction/drug effects , Rats , Receptors, Endothelin/metabolism , Sulfonamides/pharmacology
11.
Mol Biol Cell ; 11(3): 1103-12, 2000 Mar.
Article in English | MEDLINE | ID: mdl-10712523

ABSTRACT

Anchorage removal like growth factor removal induces apoptosis. In the present study we have characterized signaling pathways that can prevent this cell death using a highly growth factor- and anchorage-dependent line of lung fibroblasts (CCL39). After anchorage removal from exponentially growing cells, annexin V-FITC labeling can be detected after 8 h. Apoptosis was confirmed by analysis of sub-G1 DNA content and Western blotting of the caspase substrate poly (ADP-ribose) polymerase. Growth factor withdrawal accelerates and potentiates suspension-induced cell death. Activation of Raf-1 kinase in suspension cultures of CCL39 or Madin-Darby canine kidney cells stably expressing an estrogen-inducible activated-Raf-1 construct (DeltaRaf-1:ER) suppresses apoptosis induced by growth factor and/or anchorage removal. This protective effect appears to be mediated by the Raf, mitogen- or extracellular signal-regulated kinase kinase (MEK), and mitogen-activated protein kinase module because it is sensitive to pharmacological inhibition of MEK-1 and it can be mimicked by expression of constitutively active MEK-1 in CCL39 cells. Finally, apoptosis induced by disruption of the actin cytoskeleton with the Rho-directed toxin B (Clostridium difficile) is prevented by activation of the DeltaRaf-1:ER chimeric construct. These findings highlight the ability of p42/p44 mitogen-activated protein kinase to generate survival signals that counteract cell death induced by loss of matrix contact, cytoskeletal integrity, and extracellular mitogenic factors.


Subject(s)
Mitogen-Activated Protein Kinase 1/metabolism , Mitogen-Activated Protein Kinases/metabolism , Animals , Apoptosis , Blood , Cell Adhesion , Cells, Cultured , Cricetinae , Dogs , Enzyme Activation , MAP Kinase Signaling System , Mitogen-Activated Protein Kinase 3 , Proto-Oncogene Proteins c-raf/metabolism , rho GTP-Binding Proteins/antagonists & inhibitors , rho GTP-Binding Proteins/metabolism
12.
Biochem Pharmacol ; 59(7): 855-63, 2000 Apr 01.
Article in English | MEDLINE | ID: mdl-10718344

ABSTRACT

Early in the apoptotic process, CD95 induces a translocation of phosphatidylserine (PtdSer) from the inner to the outer leaflet of the cellular plasma membrane. In mammalian cells, PtdSer is only synthesized through a calcium-dependent exchange of the polar head group of pre-existing phospholipids, either phosphatidylcholine or phosphatidylethanolamine, by a serine. Using a pharmacological approach, we examined the influence of PtdSer synthesis on CD95-induced PtdSer exposure at the surface of Jurkat cells. We found that CD3/TCR triggering or thapsigargin treatment of Jurkat cells was accompanied both by a decreased PtdSer synthesis and by a strong reduction of CD95-induced PtdSer at the cell surface, as monitored by fluorescence-activated cell sorting (FACS) analysis of annexin V-fluorescein isothiocyanate (FITC)-labeled cells. PtdSer synthesis through the serine-base exchange enzyme system thus appeared as one of the mechanisms implicated in the recently discovered CD3/TCR-induced down-regulation of CD95-induced apoptosis. Conversely, increasing the activity of the serine-base exchange enzyme system with different drugs, either the K+ channel blocker quinine, the cationic amphiphil stearylamine, or three different calmodulin antagonists, chlorpromazine, trifluoperazine, and N-(6-aminohexyl)-5-chloro-1-naphthalene sulfonamide (W7), resulted in an increased appearance of PtdSer at the surface of CD95-treated cells. Both PtdSer synthesis and CD95-induced annexin V-FITC reactivity were abrogated in ATP-depleted cells. Also, modifying the membrane potential with valinomycin (hyperpolarization) or either gramicidin or KCl (depolarization) demonstrated a strong relationship between PtdSer synthesis and annexin V-FITC reactivity in CD95-treated cells. Together, our results indicate that CD95-induced exposure of PtdSer at the cell surface could be regulated by the activity of the serine-base exchange enzyme system.


Subject(s)
Apoptosis , Nitrogenous Group Transferases/metabolism , Phosphatidylserines/physiology , fas Receptor/metabolism , Adenosine Triphosphate/metabolism , Humans , Jurkat Cells , Kinetics , Lymphocyte Activation , Membrane Potentials , Phosphatidylserines/biosynthesis , Serine , T-Lymphocytes/drug effects , T-Lymphocytes/physiology
13.
Eur J Biochem ; 267(4): 984-92, 2000 Feb.
Article in English | MEDLINE | ID: mdl-10672006

ABSTRACT

Sodium ortho-vanadate (Na3VO4), an inhibitor of protein tyrosine phosphatase, induces a rapid (15 min) and strong inhibition of phosphatidylserine synthesis with an IC50 = 100 microM. The mode of action of Na3VO4 was compared to that of CD3 mAbs. It was found that Na3VO4 bypasses the major CD3-induced T cell activation signals including protein tyrosine phosphorylation, p56lck activation and the generation of second messengers including inositol phosphates and its subsequent Ca2+ mobilization as well as diacylglycerol production. These facts were confirmed by using a panel of Jurkat clones that differs by the expression of either tyrosine kinases involved in the CD3-induced T cell activation pathway such as p56lck, p72syk and ZAP-70 or some cell surface receptors such as the CD3/TCR complex or the CD45 phosphatase.


Subject(s)
CD3 Complex/metabolism , Calcium Signaling/drug effects , Lymphocyte Activation/drug effects , Phosphatidylserines/biosynthesis , T-Lymphocytes/immunology , Vanadates/pharmacology , Antibodies, Monoclonal , Calcium/metabolism , Calcium-Transporting ATPases/antagonists & inhibitors , Calcium-Transporting ATPases/metabolism , Cytosol/drug effects , Cytosol/metabolism , Diglycerides/analysis , Endoplasmic Reticulum/enzymology , Endoplasmic Reticulum/metabolism , Humans , Inositol 1,4,5-Trisphosphate/analysis , Jurkat Cells , Lymphocyte Specific Protein Tyrosine Kinase p56(lck)/metabolism , Phosphoric Monoester Hydrolases/antagonists & inhibitors , Phosphoric Monoester Hydrolases/metabolism , Phosphorylation/drug effects , Phosphotyrosine/metabolism , Receptors, Antigen, T-Cell/metabolism , Second Messenger Systems , Substrate Specificity , T-Lymphocytes/drug effects , T-Lymphocytes/metabolism
14.
Sci Eng Ethics ; 6(1): 41-8, 2000 Jan.
Article in English | MEDLINE | ID: mdl-11273435

ABSTRACT

Institutions in France are not yet well prepared to respond to allegations of scientific misconduct. Following a serious allegation in late 1997, INSERM, the primary organization for medical and health-related research in France, began to reflect on this subject, aided by scientists and jurists. The conclusions have resulted in establishing a procedure to be followed in cases of alleged misconduct, and also in reinforcing the application of good laboratory practices within each laboratory. Guidelines for authorship practices and scientific assessment must also be considered. Even though each institution must remain responsible for responding to allegations of scientific misconduct within its doors, INSERM would like to see national, European, and international co-ordination about the methods of such response.


Subject(s)
Biomedical Research , Government Regulation , Scientific Misconduct , Academies and Institutes , Advisory Committees , Ethics , Ethics, Research , Europe , France , Guidelines as Topic , International Cooperation
15.
Clin Exp Immunol ; 118(3): 412-6, 1999 Dec.
Article in English | MEDLINE | ID: mdl-10594560

ABSTRACT

HAART may increase CD4+ T cell counts despite a persistently detectable HIV load. The impact of HAART on apoptosis, which may play a role in the disease process in HIV-infected patients, has not been extensively studied. We performed a study to compare the level of spontaneous T cell apoptosis and anti-retroviral treatments in a cohort of HIV-1-infected patients. Data were obtained from a computerized medical record. Quantification of apoptotic cells was by cytofluorometric technique. From November 1995 to December 1997 we studied T cell apoptosis in 112 HIV-infected patients. Forty patients were classified A, 36 B and 36 C. Thirty patients were naive and 82 received an anti-retroviral treatment, 49 including a protease inhibitor (PI). The median plasma viraemia determined in 63 patients was 3.6 (range 1.3-5.6) log10. The median apoptotic cell count was 22% (range 2-73%) and 12% (range 2-60%) for CD4+ and CD8+ T cells, respectively. We did not observe any correlation between the HIV viraemia and the level of apoptosis of T cell subsets. Patients with HAART showed a lower percentage of apoptotic CD4+ T cells only: 16% (range 2-61%) versus 25% (range 5-73%) for patients receiving two nucleoside analogues (P = 0.02). This effect was significant in stage A patients and remained observable during the whole course of HIV disease. In conclusion, HAART, without any relation to plasma viraemia, is able to reduce apoptosis of CD4+ T cells.


Subject(s)
Anti-HIV Agents/therapeutic use , Apoptosis , CD4-Positive T-Lymphocytes/drug effects , HIV Infections/drug therapy , Adult , Aged , CD4-Positive T-Lymphocytes/cytology , CD8-Positive T-Lymphocytes/drug effects , Didanosine/therapeutic use , Drug Therapy, Combination , Female , HIV Infections/immunology , HIV Infections/pathology , HIV Protease Inhibitors/therapeutic use , Humans , Lamivudine/therapeutic use , Male , Middle Aged , Multivariate Analysis , Retrospective Studies , Stavudine/therapeutic use , Viral Load , Zalcitabine/therapeutic use , Zidovudine/therapeutic use
16.
Biochem Biophys Res Commun ; 266(2): 497-503, 1999 Dec 20.
Article in English | MEDLINE | ID: mdl-10600531

ABSTRACT

Phosphatidylserine synthesis as measured by the incorporation of [(3)H]serine into phosphatidylserine (PtdSer) through the serine-base exchange enzyme system (serine-BEES) is markedly inhibited in Jurkat cells treated with caffeine. The caffeine-induced inhibition was compared to that observed in cells treated with either CD3 mAb or thapsigargin. While CD3- and thapsigargin-induced inhibition was related to the release of Ca(2+) from the endoplasmic reticulum (ER), a process that deprives the serine-BEES of its major cofactor, caffeine modified PtdSer synthesis in the absence of decreased Ca(2+) content of ER. Using Jurkat clones differing by the expression of cell surface markers or protein tyrosine kinases implicated in the CD3/TCR signal transmission pathway, we have shown that CD3 mAb-induced inhibition of PtdSer synthesis necessitates the expression of both the CD3/TCR and the protein tyrosine phosphatase CD45 at the cell surface as well as the presence of p56(lck) and ZAP-70 protein tyrosine kinases. By contrast, thapsigargin, a blocker of the Ca(2+)-ATPase of the ER, known for its Ca(2+) releasing properties, inhibited PtdSer synthesis in all the Jurkat clones tested, indicating that this compound bypasses the CD3/TCR-induced signals. Despite its lack of effect on Ca(2+) release from ER and on protein tyrosine phosphorylations, caffeine inhibited PtdSer synthesis in all the Jurkat clones. The use of several cAMP-inducing drugs and of others xanthine derivatives indicated that caffeine modify PtdSer synthesis either by a direct action on the serine-BEES or by a modification of the structure of the phospholipids used as substrate by the enzyme.


Subject(s)
CD3 Complex/immunology , Caffeine/pharmacology , Calcium Signaling , Phosphatidylserines/biosynthesis , Protein-Tyrosine Kinases/metabolism , Antibodies, Monoclonal/immunology , Antibodies, Monoclonal/pharmacology , Calcium/metabolism , Calcium-Transporting ATPases/antagonists & inhibitors , Enzyme Inhibitors/pharmacology , Humans , Ionomycin/pharmacology , Jurkat Cells , Phosphorylation/drug effects , Signal Transduction , Thapsigargin/pharmacology
17.
Oncogene ; 18(27): 3963-9, 1999 Jul 08.
Article in English | MEDLINE | ID: mdl-10435619

ABSTRACT

Ligation of Fas with its natural ligand or with anti-Fas antibodies induces an apoptotic program in Fas sensitive cells. We report here the identification of the tyrosine kinase p59Fyn as a substrate for CPP32-like proteinases and more particularly caspase 3 during Fas-mediated apoptosis in Jurkat T cells. Inhibition of CPP32-like proteinases by Ac-Asp-Glu-Val-Asp-aldehyde but not by Ac-Tyr-Val-Ala-Asp-aldehyde prevents CPP32, PARP and p59Fyn cleavage indicating that CPP32 or CPP32-like proteinases are responsible for the cleavage of p59Fyn. Cleavage occurs in the N-terminal domain of p59Fyn between Asp19 and Gly20 and is accompanied by relocation of an active p57Fyn kinase to cytoplasm of Fas-stimulated Jurkat cells as judged by both biochemical and confocal microscopy experiments. Thus, p59Fyn relocation and activity may play an important role during Fas-mediated cell death in human T lymphocytes.


Subject(s)
Apoptosis , Protein-Tyrosine Kinases/metabolism , Proto-Oncogene Proteins/metabolism , T-Lymphocytes/enzymology , fas Receptor/physiology , Caspase 3 , Caspase 8 , Caspase 9 , Caspases/metabolism , Clone Cells , Humans , Hydrolysis , Jurkat Cells , Myristic Acid/metabolism , Palmitic Acid/metabolism , Peptide Fragments/metabolism , Precipitin Tests , Protein Processing, Post-Translational , Proto-Oncogene Proteins c-fyn , Signal Transduction , Substrate Specificity , T-Lymphocytes/pathology , src-Family Kinases/metabolism
18.
Clin Infect Dis ; 28(5): 1012-6, 1999 May.
Article in English | MEDLINE | ID: mdl-10452627

ABSTRACT

The mechanisms of apoptosis have become better understood, in part with the discovery of Fas/CD95. We report the case of a patient characterized by a decreased CD4+ T cell count and an overexpression of Fas/CD95 resulting in apoptosis. A 54-year-old man presented with disseminated Mycobacterium xenopi infection. Analysis showed CD4+ T lymphopenia. Tests for human immunodeficiency virus (HIV) types 1 and 2 were negative. We compared the patient with eight healthy controls and five HIV-infected patients in terms of the expression of Fas/CD95 and Fas-mediated apoptosis of peripheral T lymphocytes. The percent of CD95+ cells in lymphocytes was 98% for the patient, and the mean percent of CD95+ cells in lymphocytes +/- SD for HIV-infected patients and healthy controls was 75% +/- 16% and 36% +/- 26%, respectively. The patient had a high level of spontaneous apoptosis, and apoptotic cells were all identified as being CD4+ T cells. Monoclonal antibodies to CD95 dramatically increased apoptosis of CD4+ T cells exclusively. CD4+ T lymphopenia observed in our patient correlated with an overexpression of Fas together with spontaneous and Fas-induced apoptosis.


Subject(s)
Apoptosis/immunology , Lymphocytes/immunology , T-Lymphocytopenia, Idiopathic CD4-Positive/immunology , fas Receptor , CD4 Lymphocyte Count , HIV Infections/immunology , Humans , Male , Middle Aged , Mycobacterium Infections, Nontuberculous/complications , Mycobacterium Infections, Nontuberculous/immunology , Mycobacterium xenopi , Receptors, Interleukin-2 , Reference Values , T-Lymphocytopenia, Idiopathic CD4-Positive/etiology , fas Receptor/analysis , fas Receptor/immunology , fas Receptor/physiology
19.
Biochem Biophys Res Commun ; 256(1): 94-7, 1999 Mar 05.
Article in English | MEDLINE | ID: mdl-10066429

ABSTRACT

The effects of 2'- and 3'-O-(4-benzoylbenzoyl)-ATP (BzATP) on intracellular Ca2+ mobilization and cyclic AMP accumulation were investigated using rat brain capillary endothelial cells which express an endogenous P2Y1 receptor, human platelets which are known to express a P2Y1 receptor, and Jurkat cells stably transfected with the human P2Y1 receptor. In endothelial cells, BzATP was a competitive inhibitor of 2-methylthio ADP (2-MeSADP) and ADP induced [Ca2+]i responses (Ki = 4.7 microM) and reversed the inhibition by ADP of adenylyl cyclase (Ki = 13 microM). In human platelets, BzATP inhibited ADP-induced aggregation (Ki = 5 microM), mobilization of intracellular Ca2+ stores (Ki = 6.3 microM), and inhibition of adenylyl cyclase. In P2Y1-Jurkat cells, BzATP inhibited ADP and 2-MeSADP-induced [Ca2+]i responses (Ki = 2.5 microM). It was concluded that BzATP is an antagonist of rat and human P2Y1 receptors and of platelet aggregation. In contrast to other P2Y1 receptor antagonists (A2P5P and A3P5P) which inhibit only ADP-induced Ca2+ mobilization, BzATP inhibits both the Ca2+- and the cAMP-dependent intracellular signaling pathways of ADP. These results provide further evidence that P2Y1 receptors contribute to platelet ADP responses.


Subject(s)
Adenosine Triphosphate/analogs & derivatives , Platelet Aggregation Inhibitors/pharmacology , Platelet Aggregation/drug effects , Purinergic P2 Receptor Antagonists , Adenosine Diphosphate/analogs & derivatives , Adenosine Diphosphate/antagonists & inhibitors , Adenosine Diphosphate/pharmacology , Adenosine Triphosphate/pharmacology , Adenylyl Cyclase Inhibitors , Adenylyl Cyclases/metabolism , Alprostadil/pharmacology , Animals , Blood Platelets/drug effects , Blood Platelets/physiology , Brain/blood supply , Calcium/metabolism , Cholera Toxin/pharmacology , Cyclic AMP/pharmacology , Endothelium, Vascular/cytology , Endothelium, Vascular/drug effects , Humans , Inhibitory Concentration 50 , Jurkat Cells , Rats , Receptors, Purinergic P2/metabolism , Receptors, Purinergic P2/physiology , Receptors, Purinergic P2Y1 , Signal Transduction/drug effects , Thionucleotides/antagonists & inhibitors , Thionucleotides/pharmacology , Transfection
20.
Br J Pharmacol ; 125(4): 675-80, 1998 Oct.
Article in English | MEDLINE | ID: mdl-9831901

ABSTRACT

1. ADP is a potent agonist of rat and human P2Y1 purinoceptors. ATP is a weak competitive antagonist. This study analyses the situation in which P2Y1 receptors are exposed to ATP in the presence of exogenous ecto-nucleotidases (apyrases) that have high or low ATPase/ADPase activity ratio. 2. Rat brain capillary endothelial cells of the B10 clone express P2Y1 receptors that couple to intracellular Ca2+ mobilization. They have low endogenous ecto-ATPase and ecto-ADPase activities. 3. ATP did not raise intracellular Ca2+ in B10 cells. Addition of apyrases III or VII (1 u ml(-1)) to ATP treated cells induced large intracellular Ca2+ transients. Apyrases had no action in the absence of ATP. 4. A 1 u ml(-1) apyrase III solution generated 20 microM ADP from 0.1 mM ATP within 15 s. This concentration of ADP was sufficient to produce maximal activation of P2Y1 receptors. 5. ATP was a full agonist of P2Y1 receptors in the presence of 1 u ml(-1) apyrase III. Dose response curves for the apparent actions of ATP were bell shaped in the presence of 0.1 u ml(-1) apyrase III. Apyrase III did not alter ADP dose response curves when coincubated with ADP for 15 s. 6. Apyrase VII (1 u ml(-1)) shifted dose response curves for the actions of ADP to larger concentrations. It induced a bell shaped ATP dose response curve. 7. Results suggest that ATPDases prevent P2Y1 receptor activation by degrading ADP but may contribute to P2Y1 receptor activation by generating ADP from ATP.


Subject(s)
Adenosine Diphosphate/biosynthesis , Adenosine Triphosphatases/pharmacology , Adenosine Triphosphate/metabolism , Nucleotidases/pharmacology , Receptors, Purinergic P2/drug effects , Adenosine Diphosphate/pharmacology , Adenosine Triphosphate/pharmacology , Animals , Brain/physiology , Capillaries/physiology , Dose-Response Relationship, Drug , Endothelium, Vascular/physiology , Purinergic P2 Receptor Agonists , Rats , Receptors, Purinergic P2Y1
SELECTION OF CITATIONS
SEARCH DETAIL
...